

93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 28, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010–10167 Filed 4–29–10; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Mental Health; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; NIMH Mentoring Networks to Enhance Diversity.

*Date:* May 25, 2010.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Rebecca Steiner, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9608, Bethesda, MD 20892–9608, 301–443–4525, [steinerr@mail.nih.gov](mailto:steinerr@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; ITVA Conflicts #1.

*Date:* June 1, 2010.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Francois Boller, MD, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606,

Bethesda, MD 20892–9606, 301–443–1513, [bollefr@mail.nih.gov](mailto:bollefr@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; ITVA Conflicts #2.

*Date:* June 1, 2010.

*Time:* 4 p.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Francois Boller, MD, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892–9606, 301–443–1513, [bollefr@mail.nih.gov](mailto:bollefr@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: April 26, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010–10166 Filed 4–29–10; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Revitalizing Core Environmental Health Programs Through the Environmental Health Specialists Network (EHS-Net) Research (U01), Funding Opportunity Announcement (FOA) EH10–001, Initial Review**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the aforementioned meeting:

*Times and Dates:* 8 a.m.–5 p.m., May 20, 2010 (Closed). 8 a.m.–5 p.m., May 21, 2010 (Closed).

*Place:* JW Marriott Hotel Buckhead, 3300 Lenox Road, Atlanta, GA 30326, Telephone (404) 262–3344.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Section 10(d) of Public Law 92–463.

*Matters To Be Discussed:* The meeting will include the initial review, discussion, and evaluation of applications received in

response to “Revitalizing Core Environmental Health Programs through the EHS-Net Research (U01), FOA EH10–001.”

Agenda items are subject to change as priorities dictate.

*Contact Person For More Information:* J. Felix Rogers, PhD, M.P.H., NCIPC/ERPO, CDC, 4770 Buford Highway, NE., M/S F62, Atlanta, Georgia 30341–3724, Telephone (770) 488–4334.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 26, 2010.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2010–10164 Filed 4–29–10; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Molecular and Integrative Signal Transduction Study Section, May 25, 2010, 8 a.m. to May 26, 2010, 5:30 p.m., Hotel Palomar, 2121 P Street, NW., Washington, DC 20037 which was published in the **Federal Register** on April 14, 2010, 75 FR 19408–19409.

The meeting will be one day only May 25, 2010, from 8 a.m. to 6:30 p.m. The meeting location remains the same. The meeting is closed to the public.

Dated: April 26, 2010.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010–10148 Filed 4–29–10; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Healthcare Infection Control Practices Advisory Committee (HICPAC)**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee:

*Time and Date:* 3:30 p.m.–4:30 p.m., May 17, 2010.

*Place:* Teleconference.

*Status:* Open to the public. The toll free dial in number is (800) 369-2094 and the passcode is 3518331. Teleconference access is limited only by availability of telephone ports. Registration and teleconference logon information is also available at <http://www.cdc.gov/hicpac/>.

*Purpose:* The Committee is charged with providing advice and guidance to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), regarding the practice of hospital infection control and strategies for surveillance, prevention, and control of healthcare-associated infections (e.g., nosocomial infections), antimicrobial resistance, and related events in settings where healthcare is provided, including hospitals, ambulatory and long-term care facilities, and home health agencies. The committee shall also advise CDC on periodic updating of existing guidelines, development of new guidelines, guideline evaluation, and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

*Matters To Be Discussed:* The agenda will include a follow up discussion on the draft *Guidelines for the Prevention of Intravascular Catheter-Related Infections*.

Agenda items are subject to change as priorities dictate.

*For More Information Contact:* Michelle W. King, HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road, NE., Mailstop A-07, Atlanta, Georgia 30333, Telephone: (404) 639-2936, E-mail: [HICPAC@cdc.gov](mailto:HICPAC@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substance and Disease Registry.

Dated: April 26, 2010.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2010-10090 Filed 4-29-10; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2010-N-0001]

#### Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety and Quantitative Risk Assessment: Blood Safety and Availability; Public Workshops

**AGENCY:** Food and Drug Administration, HHS.

#### **ACTION:** Notice of public workshops.

The Food and Drug Administration (FDA) is announcing two public workshops entitled “Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety” (EID public workshop) and “Quantitative Risk Assessment: Blood Safety and Availability” (QRA public workshop), respectively. The workshops have been scheduled on consecutive days to allow interested parties to attend both. The EID public workshop is a 2-day workshop; the purpose is to review the strategies used for identification, prioritization, and response to EID that are relevant to blood, cells, tissues and organs. The workshop has been planned in partnership with the HHS Office of Science and Public Health, Centers for Disease Control and Prevention, National Institutes of Health and Health Resources Services Administration. The QRA public workshop is a 1-day workshop; the purpose is to review the scientific principles of risk assessment and to discuss the role of risk assessment in the regulatory process, specifically as it relates to blood safety and availability. The public workshops will feature presentations, case studies and round table discussions led by national and international experts from government, academia and industry.

*Date and Time:* The EID public workshop will be held on May 11 and 12, 2010, from 8:00 a.m. to 5:30 p.m., each day. The QRA public workshop will be held on May 13, 2010, from 8:30 a.m. to 5:00 p.m.

*Location:* Both public workshops will be held at the Hilton Washington DC North/Gaithersburg, 620 Perry Pkwy., Gaithersburg, MD 20877.

*Contact Person:* Persons interested in the EID public workshop should contact Rhonda Dawson, Center for Biologics Evaluation and Research (HFM-302), Food and Drug Administration, 1401 Rockville Pike, Suite 550N, Rockville, MD 20852-1448, 301-827-6129, FAX: 301-827-2843, e-mail: [rhonda.dawson@fda.hhs.gov](mailto:rhonda.dawson@fda.hhs.gov).

Persons interested in the QRA public workshop should contact Mark O. Walderhaug, Center for Biologics Evaluation and Research (HFM-210), Food and Drug Administration, 1401 Rockville Pike, Suite 400S, Rockville, MD 20852-1448, 301-827-6028, FAX: 301-827-0648, e-mail: [mark.walderhaug@fda.hhs.gov](mailto:mark.walderhaug@fda.hhs.gov).

*Registration:* Mail or fax your registration information (including name, title, firm name, address, telephone and fax numbers) to the appropriate contact person (see *Contact Person*) by May 5, 2010. There is no

registration fee for either public workshop. Early registration is recommended because seating is limited. Registration on the days of the public workshops will be provided on a space available basis beginning at 7:30 a.m.

If you need special accommodations due to a disability, please contact the appropriate contact person (see *Contact Person*) at least 7 days in advance.

**SUPPLEMENTARY INFORMATION:** FDA is announcing the following two public workshops:

#### 1. EID Public Workshop

The characterization of risk from, and prioritization of response to, emerging infectious diseases relevant to blood, cells, tissue and organ safety has always been a complicated process. In terms of preparedness, when multiple EID agents threaten blood, cells, tissue and organ safety, it can be a challenge to prioritize efforts to address the resulting risk related issues since there is no single approach or formula that guarantees an ideal prioritization process. The EID public workshop will address processes for early threat detection and risk reduction of EID agents that are relevant to blood, cells, tissues and organs, including methods of “horizon scanning,” risk assessment, risk communication and application of emerging pathogen detection and pathogen reduction technologies. In addition, the workshop will discuss research needed to help address issues regarding appropriate screening and testing for donors of human organs, cells, and tissues for transplantation.

The first day of the workshop will focus on transfusion safety and include discussions on the following topics: (1) The identification, surveillance and prioritization of EID agents in the United States (U.S.) and internationally; (2) risk assessment methodologies; and (3) tools to address EIDs, including pathogen reduction technologies, microarray sequencing and prion detection capabilities. The second day of the workshop will address organ, cell and tissue transplantation safety. Topics for discussion include the following: (1) The regulatory frameworks for cells, tissue and organ transplantation; (2) approaches to the identification and evaluation of EIDs in the U.S. and internationally; (3) risk assessment methodologies; and (4) current research priorities, limitations and opportunities.

#### 2. QRA Public Workshop

FDA’s mission to protect public health is a complex challenge that frequently requires regulators to use sophisticated analyses of risk and benefit to reach informed decisions